A Phase I clinical study to evaluate the safety and tolerability of NYX-783 in healthy volunteers

Next Previous
Trial Profile

A Phase I clinical study to evaluate the safety and tolerability of NYX-783 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs NYX-783 (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Adverse reactions
  • Sponsors Aptinyx

    • Most Recent Events

    • 07 Dec 2017 According to an Aptinyx media release, the Company has initiated this Phase I trial and plans to advance NYX-783 into efficacy studies next year.
    • 07 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top